J Timpka1, T Fox2, K Fox2, H Honig2, P Odin1,2, P Martinez-Martin3, A Antonini4, K Ray Chaudhuri5. 1. Department of Clinical Sciences, Neurology, Lund University, Lund, Sweden. 2. Department of Neurology, Central Hospital, Bremerhaven, Germany. 3. National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain. 4. Parkinson's Disease and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, Italy. 5. National Parkinson Foundation Centre of Excellence, King's College Hospital, King's College, London, UK.
Abstract
OBJECTIVES: We wanted to investigate whether continuous intrajejunal levodopa-carbidopa intestinal gel (LCIG) therapy has an antidyskinetic effect in patients with Parkinson's disease (PD) and troublesome dyskinesias. We also sought to examine the effect of LCIG therapy on motor function and health-related quality of life (HRQoL). MATERIALS AND METHODS: This open-label pilot study used a single group pre-post design with follow-up at 6 months. Nine patients with PD who reported to spend at least 3 h per day in on with troublesome dyskinesia were included. The patients were examined at baseline using clinical and self-assessment measures and then switched from peroral/transdermal pharmacotherapy to LCIG therapy. Data collection was repeated 6 months after the pharmaceutical intervention. Nonparametric statistical methods were used for data analyses. RESULTS: The mean time spent in on with troublesome dyskinesia per day after 6 months of LCIG therapy decreased by 47% (P < 0.05). This observation was paralleled by a 112% increase in mean time spent in on without troublesome dyskinesia (P < 0.01). Patient self-assessment of dyskinesia intensity on the visual analog scale displayed a 90% reduction of mean dyskinesia intensity (P < 0.01) and patients also exhibited less dyskinesia during standardized levodopa tests. Furthermore, we noted improvements in motor function and HRQoL. CONCLUSIONS: In this pilot study, we found indications that LCIG therapy has a substantial antidyskinetic effect and could be an alternative also for PD patients with dyskinesias as a major symptom. However, further studies with blinded evaluation and larger numbers of patients are warranted to confirm the findings.
OBJECTIVES: We wanted to investigate whether continuous intrajejunal levodopa-carbidopa intestinal gel (LCIG) therapy has an antidyskinetic effect in patients with Parkinson's disease (PD) and troublesome dyskinesias. We also sought to examine the effect of LCIG therapy on motor function and health-related quality of life (HRQoL). MATERIALS AND METHODS: This open-label pilot study used a single group pre-post design with follow-up at 6 months. Nine patients with PD who reported to spend at least 3 h per day in on with troublesome dyskinesia were included. The patients were examined at baseline using clinical and self-assessment measures and then switched from peroral/transdermal pharmacotherapy to LCIG therapy. Data collection was repeated 6 months after the pharmaceutical intervention. Nonparametric statistical methods were used for data analyses. RESULTS: The mean time spent in on with troublesome dyskinesia per day after 6 months of LCIG therapy decreased by 47% (P < 0.05). This observation was paralleled by a 112% increase in mean time spent in on without troublesome dyskinesia (P < 0.01). Patient self-assessment of dyskinesia intensity on the visual analog scale displayed a 90% reduction of mean dyskinesia intensity (P < 0.01) and patients also exhibited less dyskinesia during standardized levodopa tests. Furthermore, we noted improvements in motor function and HRQoL. CONCLUSIONS: In this pilot study, we found indications that LCIG therapy has a substantial antidyskinetic effect and could be an alternative also for PDpatients with dyskinesias as a major symptom. However, further studies with blinded evaluation and larger numbers of patients are warranted to confirm the findings.
Authors: Maria José Catalán; Angelo Antonini; Matilde Calopa; Ovidiu Băjenaru; Oriol de Fábregues; Adolfo Mínguez-Castellanos; Per Odin; José Manuel García-Moreno; Stephen W Pedersen; Zvezdan Pirtošek; Jaime Kulisevsky Journal: eNeurologicalSci Date: 2017-07-02
Authors: Oriol De Fabregues; Joan Dot; Monder Abu-Suboh; Jorge Hernández-Vara; Alex Ferré; Odile Romero; Marta Ibarria; José Luis Seoane; Nuria Raguer; Carolina Puiggros; Maria Rosa Gómez; Manuel Quintana; Josep Ramon Armengol; José Alvarez-Sabín Journal: Brain Behav Date: 2017-07-07 Impact factor: 2.708
Authors: Michelle Burack; Jason Aldred; Cindy Zadikoff; Arvydas Vanagunas; Kevin Klos; Bahri Bilir; Hubert H Fernandez; David G Standaert Journal: Mov Disord Clin Pract Date: 2018-06-27
Authors: Belinda Cruse; Hugo Morales-Briceño; Florence C F Chang; Neil Mahant; Ainhi D Ha; Samuel D Kim; Nigel Wolfe; Vu Kwan; David S Tsui; Jane M Griffith; Donna Galea; Victor S C Fung Journal: NPJ Parkinsons Dis Date: 2018-11-20
Authors: James T Boyd; Cindy Zadikoff; Janet A Benesh; Jorge Zamudio; Weining Z Robieson; Pavnit Kukreja; Masayuki Yokoyama; Mustafa S Siddiqui Journal: Clin Park Relat Disord Date: 2019-12-11